Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up Women only

Almond oil versus 2% hydroquinone for facial pigmentation

Official title: Prospective Evaluation of Topical Almond Oil vs Hydroquinone on the Appearance of Facial Pigmentation and the Stability of the Microbiome

Run by University of California, Davis · NCT04875715 · Data updated 2026-11-12

This test compares nightly almond oil and 2% hydroquinone to see which better reduces facial pigmentation in premenopausal women with Fitzpatrick skin types 3–6.

More Skin Pigmentation trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment50 (estimated)
SponsorUniversity of California, Davis
Academic / other
Locations1 site (Sacramento, California)
StatusRecruiting
StartedJuly 1, 2021
Main results expectedDecember 1, 2026
Study endsDecember 1, 2026
Registry record updatedSeptember 14, 2026
Trial IDNCT04875715 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Premenopausal women with Fitzpatrick skin types 3–6 who are not allergic to nuts and can attend in-person visits at UC Davis are ideal candidates.

Probably not a fit

People with nut allergies, current smokers or heavy former smokers, those on unstable hormonal therapies, or those who had recent facial cosmetic procedures are unlikely to qualify and may not benefit from the interventions tested.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, open-label comparison enrolling 50 premenopausal women with Fitzpatrick skin types 3–6, with 25 assigned to nightly almond oil and 25 to nightly 2% hydroquinone for four months. Investigators will collect facial images and measure skin pigment, skin hydration, and sebum excretion rate at baseline and follow-up visits. The study will also analyze changes in the facial skin microbiome associated with each topical treatment. All visits take place at the UC Davis Department of Dermatology Clinical Trials Unit.

Why it matters

Potential benefit: If successful, the study could identify a gentler, natural topical option that reduces facial pigmentation and favorably influences the skin microbiome.

How similar studies have gone: Hydroquinone is a well-established treatment for hyperpigmentation, whereas using topical almond oil for pigment reduction and microbiome changes is largely novel with limited clinical evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Premenopausal women of Fitzpatrick skin types 3 to 6

Exclusion Criteria:

* Those with a nut allergy
* Smoking is an independent risk factor and serves as a confounder for the development of facial aging \[18\]. Therefore current smokers, those that have smoked within the past year, and former smokers with greater than a 20 pack year history of smoking will be excluded.
* Those with an autoimmune photosensitive condition or a known genetic condition with a deficiency in collagen production (such as Ehlers-Danlos syndrome) will be excluded as this can be a confounder for facial photoaging.
* Hormonal medications or therapies will not be allowed unless they have been stable on their medications for at least 2 months. Examples include oral contraceptives, progesterone-based injections, and estrogen based hormonal replacement therapy.
* Those who have undergone any cosmetic procedures to the face in the 4 months prior to enrollment in the opinion of the investigator. People that have undergone deeper chemical peels (TCA based peels) within 1 year prior to enrollment will also not be eligible.
* Individuals who are unwilling to discontinue vitamin E containing supplements and food sources during the washout and intervention.
* Individual who are unwilling to discontinue topical cosmetic products during the duration of the study.
* Individuals who are not willing to engage in a two-week washout on topical treatments known to affect facial pigmentation and these agents will be restricted during the study period as well. These include topicals that contain:

  * Retinoids such as tretinoin, adapalene, retinol.
  * Antioxidant ingredients such as vitamin C or vitamin E.
  * Pigment-reducing agents such as hydroquinone, azelaic acid, kojic acid per the discretion of the investigator except for the hydroquinone that is provided in this study.
  * Topicals that contain a nut oil or nut extract as part of their ingredient list.
* Furthermore, subjects will be asked to refrain from use of any other topical products for one week prior to each visit apart from the study agents supplied from this study.

Where it's running

  • UC Davis Department of Dermatology, Clinical Trials Unit
    Sacramento, California, United States
    Recruiting

Study contacts

  • Principal investigator: Raja Sivamani, MD MS AP — UC Davis Dermatology
  • Study coordinator: Iryna Rybak
  • Email: irybak@ucdavis.edu
  • Phone: 916-551-2636

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.